Skip to Content

Frequently Searched

Supported by

Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancer with MET Exon 14 Alterations

About this PQI in Action

This PQI in Action is a follow up to the Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancer with MET Exon 14 Alterations PQI and explores how the medically integrated teams at Florida Cancer Specialists & Research Institute, Mayo Clinic, and Texas Oncology collaborate and utilize the information found in the PQI as part of their daily practice.

More About This PQI in Action

Find a PQI

PQI

 PQI: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancer with MET Exon 14 Alterations

Last Updated: 03/05/2024 12:00 am